Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Impact of prenylation inhibition on RAS mutant tumors in preclinical studies].

Magyar onkologia - 9 Dec 2019

Baranyi Marcell, Molnár Eszter, Rittler Dominika, Hegedûs Balázs, Tímár József

Abstract excerpt

Oncogenic mutation of RAS occurs in 20-25% of all malignancies. Our research group have examined inhibition of RAS prenylation on RAS wild type and RAS mutated melanoma, colorectal cancer and lung adenocarcinoma cell lines. Effects of clinically approved bisphosphonate (zoledronic acid) and its lipophilic derivate (BPH1222) on cell viability and cell signaling were determined. In models of melanoma and colorectal...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Line, Tumor
Share to Cell Survival
Share to Diphosphonates

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Neoplasms

Share to ras Proteins

Share to Signal Transduction

Source

Identifiers

PMID: 31821387

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Impact of prenylation inhibition on RAS mutant tumors in preclinical studies].PMID 31821387Read ↗

Prenylation inhibition-induced cell death in melanoma: reduced sensitivity in BRAF mutant/PTEN wild-type melanoma cells.Semantic proximity Read ↗

KRAS-mutation status dependent effect of zoledronic acid in human non-small cell cancer preclinical models.Semantic proximity Read ↗

RAS: Target for Cancer TherapySemantic proximity Read ↗

Radiosensitizing effects of the prenyltransferase inhibitor AZD3409 against RAS mutated cell lines.Semantic proximity Read ↗

Farnesyltransferase Inhibitor as Anticancer AgentSemantic proximity Read ↗

Farnesylated proteins as anticancer drug targets: from laboratory to the clinic.Semantic proximity Read ↗

Inhibiting Ras prenylation increases the radiosensitivity of human tumor cell lines with activating mutations of ras oncogenes.Semantic proximity Read ↗

Farnesyltransferase inhibitors: potential role in the treatment of cancer.Semantic proximity Read ↗

Transformation by Hras(G12V) is consistently associated with mutant allele copy gains and is reversed by farnesyl transferase inhibition.Semantic proximity Read ↗

[Oncogen dependent regulation of the migration and proliferation of human tumor cells].Semantic proximity Read ↗

Innovative treatment programs against cancer. I. Ras oncoprotein as a molecular target.Semantic proximity Read ↗

N-Arachidonoyl Dopamine Inhibits NRAS Neoplastic Transformation by Suppressing Its Plasma Membrane TranslocationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.